Related references
Note: Only part of the references are listed.Fenofibrate reduces osteonecrosis without affecting antileukemic efficacy in dexamethasone-treated mice
Emily R. Finch et al.
HAEMATOLOGICA (2021)
Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia A Randomized Clinical Trial
Shuhong Shen et al.
JAMA ONCOLOGY (2020)
Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis
Emily R. Finch et al.
PEDIATRIC BLOOD & CANCER (2019)
Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622
William B. Slayton et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Osteonecrosis in Pediatric Patients with Acute Lymphoblastic Leukemia (ALL): A Single-Center Cohort Analysis
Erica Brivio et al.
BLOOD (2018)
Asparaginase Potentiates Glucocorticoid-Induced Osteonecrosis in a Mouse Model
Chengcheng Liu et al.
PLOS ONE (2016)
Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia
Laura B. Ramsey et al.
PLOS ONE (2015)
Host thiopurine methyltransferase status affects mercaptopurine antileukemic effectiveness in a murine model
Laura B. Ramsey et al.
PHARMACOGENETICS AND GENOMICS (2014)
Primary Epiphyseal Arteriopathy in a Mouse Model of Steroid-Induced Osteonecrosis
Laura J. Janke et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutation
Naoto Takahashi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2012)
Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial
Leonard A. Mattano et al.
LANCET ONCOLOGY (2012)
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia
Nidal Boulos et al.
BLOOD (2011)
Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium
Richard Aplenc et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib
Neil P. Shah et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
A Mouse Model for Glucocorticoid-Induced Osteonecrosis: Effect of a Steroid Holiday
Lei Yang et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2009)
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
Kimmo Porkka et al.
BLOOD (2008)
Identification of the human enzymes involved in the oxidative metabolism of dasatinib: An effective approach for determining metabolite formation kinetics
Lifei Wang et al.
DRUG METABOLISM AND DISPOSITION (2008)
Metabolism and disposition of dasatinib after oral administration to humans
Lisa J. Christopher et al.
DRUG METABOLISM AND DISPOSITION (2008)
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice
Yiguo Hu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia
RT Williams et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Food intake, water intake, and drinking spout side preference of 28 mouse strains
AA Bachmanov et al.
BEHAVIOR GENETICS (2002)
Share Paper
